Longeveron Announces
Abstract Highlighting Data from Phase 1 Alzheimer’s Disease Trial
Accepted for Developing Topics Presentation at the 2021 Annual
Alzheimer's Association International Conference
Abstract presentation highlights safety and potential efficacy of Lomecel-B infusion in patients with mild Alzheimer’s Disease
MIAMI, June 24, 2021 (GLOBE NEWSWIRE) -- Longeveron
Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing
cellular therapies for aging-related and chronic disease, announced
today that an abstract summarizing the results of its Phase 1 trial of
Lomecel-B infusion for patients with mild Alzheimer’s disease has been
accepted for a Developing Topics poster presentation at the 2021 Annual
Alzheimer's Association International Conference, being held July 26-30,
2021 in Denver, CO and online.
The abstract is titled “Safety
and Efficacy of Lomecel-B in Patients with Mild Alzheimer’s Disease:
Results of a Double-Blinded, Randomized, Placebo-Controlled, Phase 1
Clinical Trial.” This 33 subject study was supported by two competitive Part the Cloud Challenge on Neuroinflammation
grants from the Alzheimer’s Association. The previously announced
results can be found on the “News and Events” page in the Investors
section of Longeveron’s website at investors.longeveron.com.
“We
are extremely pleased that the Alzheimer’s Association has recognized
our trial and data by giving us this opportunity to present the findings
in poster presentation form at the prestigious AAIC,” said Dan Gincel,
Ph.D., Senior Vice President of Strategic Collaborations &
Scientific Affairs at Longeveron. “The trial met its primary endpoint of
demonstrating safety and feasibility, and importantly, no Alzheimer’s
Related Imaging Abnormalities (ARIA), after infusion with Lomecel-B.
Furthermore, we were thrilled to observe that treatment with low-dose
Lomecel-B slowed cognitive decline compared to the placebo group as
measured by the Mini Mental State Exam (MMSE) score. As a result, we
look forward to advancing Lomecel-B into a Phase 2 clinical trial in the
second half of 2021.”
Information about the Annual Alzheimer's Association International Conference can be found at www.alz.org/aaic/overview.asp.
About Longeveron Inc.
Longeveron
is a clinical stage biotechnology company developing cellular therapies
for specific aging-related and life-threatening conditions. The
Company’s lead investigational product is the LOMECEL-B™ cell-based
therapy product (“Lomecel-B”), which is derived from culture-expanded
medicinal signaling cells (MSCs) that are sourced from bone marrow of
young, healthy adult donors. Longeveron believes that by using the same
cells that promote tissue repair, organ maintenance, and immune system
function, it can develop safe and effective therapies for some of the
most difficult disorders associated with the aging process and other
medical disorders. Longeveron is currently sponsoring Phase 1 and 2
clinical trials in the following indications: Aging Frailty, Alzheimer’s
disease, and hypoplastic left heart syndrome (HLHS). The Company’s
mission is to advance Lomecel-B and other cell-based product candidates
into pivotal Phase 3 trials, with the goal of achieving regulatory
approvals, subsequent commercialization and broad use by the healthcare
community. Additional information about the Company is available at www.longeveron.com.
Forward-Looking Statements
Certain
statements in this press release that are not historical facts are
forward-looking statements that reflect management's current
expectations, assumptions, and estimates of future performance and
economic conditions, and involve risks and uncertainties that could
cause actual results to differ materially from those anticipated by the
statements made herein. Forward-looking statements are generally
identifiable by the use of forward-looking terminology such as
"believe," "expects," "may," "looks to," "will," "should," "plan,"
"intend," "on condition," "target," "see," "potential," "estimates,"
"preliminary," or "anticipates" or the negative thereof or comparable
terminology, or by discussion of strategy or goals or other future
events, circumstances, or effects. Moreover, forward-looking statements
in this release include, but are not limited to, statements about the
ability of our clinical trials to demonstrate safety and efficacy of our
product candidates, and other positive results; the timing and focus of
our ongoing and future preclinical studies and clinical trials; the
size of the market opportunity for our product candidates, the
beneficial characteristics, safety, efficacy and therapeutic effects of
our product candidates; our ability to obtain and maintain regulatory
approval of our product candidates, our plans and ability to obtain or
protect intellectual property rights, including extensions of existing
patent terms where available and our ability to avoid infringing the
intellectual property rights of others. Further information relating to
factors that may impact the Company's results and forward-looking
statements are disclosed in the Company's filings with the SEC. The
forward-looking statements contained in this press release are made as
of the date of this press release, and the Company disclaims any
intention or obligation, other than imposed by law, to update or revise
any forward-looking statements, whether as a result of new information,
future events, or otherwise.
BioFlorida is the voice of Florida's life sciences industry, representing 8,600 establishments and research organizations in the BioPharma, MedTech, Digital Health and Health Systems that collectively employ nearly 107,000 Floridians. Source: TEConomy/BIO (released 2022)
Print Page
Email to a Friend
